Pharsight

Amryt patents expiration

1. Juxtapid patents expiration

JUXTAPID's oppositions filed in EPO
JUXTAPID Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9861622 AMRYT Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects
Mar, 2025

(11 months from now)

US8618135 AMRYT Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects
Mar, 2025

(11 months from now)

US9265758 AMRYT Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects
Mar, 2025

(11 months from now)

US9364470 AMRYT Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects
Mar, 2025

(11 months from now)

US10555938 AMRYT Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects
Mar, 2025

(11 months from now)

US9433617 AMRYT Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects
Mar, 2025

(11 months from now)

US10016404 AMRYT Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects
Mar, 2025

(11 months from now)

US7932268 AMRYT Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects
Aug, 2027

(3 years from now)

Drugs and Companies using LOMITAPIDE MESYLATE ingredient

Market Authorisation Date: 21 December, 2012

Treatment: A dosing regimen for the treatment of hypercholesterolemia and hyperlipidemia in patients with homozygous familial hypercholesterolemia using at least three step-wise increasing doses; A dosing regime...

Dosage: CAPSULE;ORAL

More Information on Dosage

JUXTAPID family patents

Family Patents

2. Mycapssa patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9265812 AMRYT Pharmaceutical compositions and related methods of delivery
Sep, 2029

(5 years from now)

US8535695 AMRYT Pharmaceutical compositions and related methods of delivery
Sep, 2029

(5 years from now)

US9566246 AMRYT Pharmaceutical compositions and related methods of delivery
Sep, 2029

(5 years from now)

US8329198 AMRYT Pharmaceutical compositions and related methods of delivery
Sep, 2029

(5 years from now)

US11052126 AMRYT Method of treating diseases
Feb, 2036

(11 years from now)

US10695397 AMRYT Method of treating diseases
Feb, 2036

(11 years from now)

US10238709 AMRYT Method of treating diseases
Feb, 2036

(11 years from now)

US11338011 AMRYT Method of treating diseases
Feb, 2036

(11 years from now)

US11510963 AMRYT Method of treating diseases
Feb, 2036

(11 years from now)

US11141457 AMRYT Oral octreotide therapy and contraceptive methods
Dec, 2040

(16 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product (NP) Jun 26, 2023

Drugs and Companies using OCTREOTIDE ACETATE ingredient

Market Authorisation Date: 26 June, 2020

Treatment: Use of oral octreotide for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide; Use of oral octreotide for long-term main...

Dosage: CAPSULE, DELAYED RELEASE;ORAL

More Information on Dosage

MYCAPSSA family patents

Family Patents